Veracyte Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Veracyte wird ein jährliches Gewinn- und Umsatzwachstum von 122.1% bzw. 9.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 126.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 0.7% betragen.

Wichtige Informationen

122.1%

Wachstumsrate der Gewinne

126.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.3%
Wachstumsrate der Einnahmen	9.9%
Zukünftige Eigenkapitalrendite	0.7%
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09

Recent updates

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Jul 02

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Jun 06

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Apr 18

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Mar 18

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Jul 13

Veracyte: Not A Healthy Diagnosis

May 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:VCYT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	493	21	65	N/A	5
12/31/2025	448	10	45	N/A	9
12/31/2024	406	-4	17	N/A	9
3/31/2024	375	-68	26	37	N/A
12/31/2023	361	-74	34	44	N/A
9/30/2023	343	-50	29	38	N/A
6/30/2023	329	-29	23	31	N/A
3/31/2023	311	-30	7	14	N/A
12/31/2022	297	-37	-1	8	N/A
9/30/2022	284	-43	-1	6	N/A
6/30/2022	268	-49	-10	-2	N/A
3/31/2022	251	-48	-7	0	N/A
12/31/2021	220	-76	-37	-32	N/A
9/30/2021	187	-73	-43	-38	N/A
6/30/2021	157	-63	-39	-35	N/A
3/31/2021	123	-65	-48	-45	N/A
12/31/2020	117	-35	-13	-10	N/A
9/30/2020	113	-34	-13	-10	N/A
6/30/2020	113	-31	-16	-13	N/A
3/31/2020	122	-22	-10	-8	N/A
12/31/2019	120	-13	-6	-3	N/A
9/30/2019	116	-8	-8	-6	N/A
6/30/2019	109	-12	-9	-6	N/A
3/31/2019	101	-16	-10	-7	N/A
12/31/2018	92	-23	-15	-14	N/A
9/30/2018	86	-28	-20	-18	N/A
6/30/2018	80	-31	-23	-21	N/A
3/31/2018	76	-32	-25	-23	N/A
12/31/2017	72	-31	N/A	-24	N/A
9/30/2017	71	-27	N/A	-22	N/A
6/30/2017	72	-26	N/A	-25	N/A
3/31/2017	68	-29	N/A	-27	N/A
12/31/2016	65	-31	N/A	-28	N/A
9/30/2016	61	-35	N/A	-27	N/A
6/30/2016	55	-38	N/A	-23	N/A
3/31/2016	52	-36	N/A	-27	N/A
12/31/2015	50	-34	N/A	-27	N/A
9/30/2015	48	-34	N/A	-33	N/A
6/30/2015	45	-33	N/A	-35	N/A
3/31/2015	42	-30	N/A	-30	N/A
12/31/2014	38	-29	N/A	-28	N/A
9/30/2014	33	-27	N/A	-22	N/A
6/30/2014	29	-26	N/A	-21	N/A
3/31/2014	25	-25	N/A	-19	N/A
12/31/2013	22	-26	N/A	-19	N/A
9/30/2013	20	-25	N/A	-20	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VCYT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: VCYT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: VCYT wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: VCYTDie Einnahmen des Unternehmens (9.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: VCYTDie Einnahmen des Unternehmens (9.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: VCYTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (0.7%).

Veracyte Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$0.052 loss

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Forecast to breakeven in 2025

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024

Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024

Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023

Recent updates

Veracyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Veracyte, Inc. Announces New Afirma Grid Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Consensus EPS estimates upgraded to US$0.052 loss

New major risk - Revenue and earnings growth

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024

Veracyte, Inc., Annual General Meeting, Jun 12, 2024

Veracyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024

Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors

Veracyte, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Veracyte, Inc. (NasdaqGM:VCYT) completed the acquisition of C2i Genomics, Inc.

Veracyte, Inc. (NasdaqGM:VCYT) has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Veracyte, Inc. Reports Consolidated Impairment Charges for the Quarter Ended September 30, 2023

Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023

Veracyte, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Veracyte, Inc. Announces New Data from A Large, Randomized Phase 3 Trial Reinforce the Value of the Decipher Prostate Genomic Classifier in Helping Physicians Make More Informed Treatment Decisions for Their Patients with Prostate Cancer

Veracyte, Inc. Announces New Data Presented At the 2023 American Thyroid Association Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023

Veracyte, Inc. Announces Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

Consensus estimates of losses per share improve by 11%

Veracyte, Inc. Announces Resignation of Tina S. Nova as General Manager, Urological Cancers Effective September 4, 2023

Veracyte, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Veracyte, Inc. Announces New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

Independent Director notifies of intention to sell stock

Veracyte Announces That New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Co-Founder & Executive Chairwoman notifies of intention to sell stock

Co-Founder & Executive Chairwoman notifies of intention to sell stock

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Announces New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

Veracyte, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Co-Founder & Executive Chairwoman exercised options and sold US$682k worth of stock

Veracyte, Inc. Announces Resignation of Giulia C. Kennedy as Global Chief Scientific Officer and Chief Medical Officer

Co-Founder & Executive Chairwoman exercised options and sold US$1.4m worth of stock

Independent Director recently sold US$181k worth of stock

Consensus estimates of losses per share improve by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Raises Revenue Guidance for the Year 2022

Veracyte, Inc. Announces New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

Veracyte, Inc. Announces Data That Provide New Insights into Thyroid Tumor Behavior

New Data Presented At American College of Chest Physicians 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Co-Founder & Executive Chairwoman exercised options to buy US$188k worth of stock.

Veracyte, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Veracyte, Inc. Publishes New Data in JNCI Demonstrate its Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

Veracyte, Inc. Names John Leite as Senior Vice President and General Manager of Pulmonology & Market Access

Veracyte, Inc. Announces That New Data from a Phase 3 Trial of the Multi-Center, Multi-National, Randomized Stampede Platform Protocol

Veracyte, Inc. Announces New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for Car T-Cell Therapy in Patients with Large B-Cell Lymphoma

Veracyte, Inc. Appoints Eliav Barr to Its Board of Directors

Co-Founder & Executive Chairwoman recently sold US$3.4m worth of stock

Consensus estimates of losses per share improve by 10%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations